Guidance for market authorization requirements for COVID-19 drugs: Overview
This document provides guidance to drug manufacturers seeking authorization for their drug manufactured, sold, or represented for use in relation to COVID-19. The guidance explains recent changes to the regulatory process for new COVID-19 drugs.
- Publisher - Current Organization Name: Health Canada
- Licence: Open Government Licence - Canada
Data and Resources
-
Guidance for market authorization requirements for COVID-19 drugs: OverviewHTMLEnglish publication HTML
-
Guidance for market authorization requirements for COVID-19 drugs: OverviewHTMLFrench publication HTML